Back to Resource Library
DISCOVER study for HIV pre-exposure prophylaxis (PrEP): F/TAF has a more rapid onset and longer sustained duration of HIV protection compared with F/TDF
7 July 2022
In the DISCOVER study, F/TAF oral PrEP (Descovy) was statistically noninferior to F/TDF oral PrEP (Truvada). However, there were numerically 53% fewer HIV infections in the F/TAF arm vs. F/TDF . This study explores HIV risk, STIs, adherence, and pharmacokinetic data to evaluate this imbalance.